Back to search
FDAFDA · Food and drugs·Recall number D-0223-2025

Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-103-01

Published February 12, 2025 · Recall initiated: December 20, 2024

Summary

FDA records drug Class I recall D-0223-2025, published February 12, 2025 and initiated December 20, 2024. Recalling firm: ENDO USA, Inc.; Status: Ongoing; Reported quantity: 44,397 amber glass vials; Lot: All lots within expiry. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin® (epinephrine injection, USP)

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ENDO USA, Inc.
Distributor
USA nationwide.
Lot
All lots within expiry
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-103-01 recalled?

Yes. FDA published recall D-0223-2025 on February 12, 2025. Reported hazard: Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin® (epinephrine injection, USP)

What should I do if I have this product?

Voluntary: Firm initiated · Press Release